Roivant Sciences Ltd. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Basel, switzerland and london and new york, april 02, 2024 (globe newswire) -- roivant (nasdaq: roiv) and priovant therapeutics today announced positive results from the phase 2 study (neptune) evaluating brepocitinib in non-anterior non-infectious uveitis (niu), showing the strongest efficacy data in niu observed to date. roivant also announced that its board of directors has authorized a share repurchase program for up to $1.5 billion of the company's common shares, including the repurchase of all 71.3 million shares held by sumitomo pharma at a purchase price of $9.10 per share. the aggregate purchase price for the sumitomo pharma transaction is approximately $648.4 million and will reduce roivant's shares outstanding as of february 9, 2024 by approximately 9%.

Basel, switzerland and london and new york, feb. 13, 2024 (globe newswire) -- roivant (nasdaq: roiv) today reported its financial results for the third quarter ended december 31, 2023, and provided a business update.

New york, dec. 20, 2023 (globe newswire) -- immunovant, inc. (nasdaq: imvt), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week phase 2 clinical trial of batoclimab in patients with graves' disease meaningfully exceeded 50% response rates.

Basel, switzerland and london and new york, dec. 14, 2023 (globe newswire) -- roivant (nasdaq: roiv) announced today the completion of the previously announced acquisition by roche (six: ro, rog; otcqx: rhhby) of telavant, for an upfront payment of approximately $7.1 billion. telavant holds the rights in the us and japan to rvt-3101, a promising new therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and crohn's disease. prior to the closing of the transaction, roivant owned 75% of the issued and outstanding shares of common stock and preferred stock of telavant, on an as-converted basis. an additional payment of $150 million in cash is payable upon the completion of a near-term milestone.

Basel, switzerland and london and new york, nov. 13, 2023 (globe newswire) -- roivant (nasdaq: roiv) today reported its financial results for the second quarter ended september 30, 2023, and provided an update on the business.

Roivant Sciences operates with an innovative business model through its subsidiaries, specializing in specific therapeutic areas such as immuno-dermatology and autoimmune disorders. Notable achievements include the sale of Telavant to Roche, the successful performance of Vtama cream for psoriasis, and advancements in clinical trials for atopic dermatitis and IMVT-1402 antibody development. Despite the lack of immediate catalysts and ongoing cash burn, the stock trades at a substantial discount relative to its sector, making it a "buy" at current levels.

Roivant Sciences stock moved lower on Monday after the biopharmaceutical company announced that its lupus therapeutic oral brepocitinib failed to meet the primary endpoint in a Phase 2 study. The company said it plans to continue progressing the drug in other indications outside of Systemic Lupus Erythematosus (SLE) given its favorable safety and tolerability profile, six other positive Phase 2 studies, and the active arm performance of this study.

Roivant Sciences Ltd. shares ROIV fell 3% premarket on Monday after the company said the experimental treatment brepocitinib failed to meet its main goal in a trial involving patients with moderate to severe lupus.

Roivant Sciences said on Monday its experimental drug to treat autoimmune disease systemic lupus erythematosus (SLE) failed to meet the main goal of reducing symptoms in a mid-stage study.

Roivant Sciences has reported a third-quarter earnings miss but revenue that topped analysts' expectations, sending its shares higher in Monday premarket trading. The company also said it has sufficient cash to fund its programs after it and Pfizer agreed to sell Telavant, manufacturer of an inflammatory bowel disease drug, to Roche for $7.25 billion.

BASEL, LONDON, and NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 13, 2023, to report its financial results for the second quarter ended September 30, 2023, and provide a business update.

Roche Holding AG acquires Telavant Holdings for $7.1B upfront and $150M milestone payment, potentially very interesting deal. Roivant Sciences owns a 75% equity interest in Telavant Holdings. Curiously, Roivant Sciences stock sold off on the news.

Monday, Roivant Sciences announced an asset sale to Roche. The biotech is slated to earn $5.2 billion upon closing, plus a $110 milestone payment once a late-stage trial commences.

London-based biotech firm Roivant Sciences (ROIV) agreed to sell its Telavant Holdings unit, which is co-owned by Pfizer (PFE), to Roche Holding for $7.1 billion.

Shares of Roivant Sciences Ltd. ROIV, -1.13% and Pfizer Inc. PFE, -1.73% gained ground premarket on Monday after Roche Holding AG RHHBY, +0.51% agreed to buy immunology company Telavant for $7.1 billion.